Interesting T2DM: Weight Loss Device & Meds Update

October 19, 2016

Samantha J. Peterson

Our October list of news and research includes FDA approval of a new weight loss device, a comparison of canagliflozin & glimepiride, and more.

We present a selection of interesting news and research for the month of October focusing on type 2 diabetes. See the slide legends for links to the article summaries.Be on the lookout for our regular Interesting Endocrinology series later this month, which will cover type 1 diabetes and other endocrine disorders.Â

Interesting Type 2 Diabetes: Weight Loss Device & Meds Update

Sugar Industry and Coronary Heart Disease Research. A Historical Analysis of Internal Industry Documents. Abstract Link. ****Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Abstract Link.

Association Between Glycaemic Control and Common Infections in People with Type 2 Diabetes: a Cohort Study. Abstract link.****Association of GA/HbA1c Ratio and Cognitive Impairment in Subjects with Type 2 Diabetes Mellitus. Abstract link.

Ghrelin Is a Possible New Predictor Associated with Executive Function in Patients with Type 2 Diabetes Mellitus. Abstract link. ****Lifetime Duration of Depressive Disorders in Patients with T2D. Abstract link.

Primary Care Patients’ Willingness to Participate in Comprehensive Weight Loss Programs: from the WWAMI Region Practice and Research Network. Abstract link.****High-Protein Intake during Weight Loss Therapy Eliminates the Weight-Loss-Induced Improvement in Insulin Action in Obese Postmenopausal Women. Abstract link.

Addition or Switch to Insulin Therapy in People Treated with GLP-1 Receptor Agonists: a Real World Study in 66,583 Patients. Abstract link.****Metformin Effect on Non-Targeted Metabolite Profiles in Patients with Type 2 Diabetes and Multiple Murine Tissues. Abstract link.

A Post-Hoc Analysis of the Comparative Efficacy of Canagliflozin and Glimepiride in the Attainment of Type 2 Diabetes-Related Quality Measures. Abstract link. ****Treatment Discontinuation of Oral Hypoglycemic Agents and Healthcare Utilization among Patients with Diabetes. Abstract link.

Obalon Announces FDA Approval of Obalon Balloon System. Press release. ****Low Adoption of Weight Loss Medications: a Comparison of Prescribing Patterns of Antiobesity Pharmacotherapies and SGLT2s. Abstract Link.

Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults. Abstract link.****Pharmacologic Activation of Estrogen Receptor Î² Increases Mitochondrial Function, Energy Expenditure, and Brown Adipose Tissue. Abstract link.